Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).
about
Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studiesDipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative reviewLixisenatide in type 2 diabetes: latest evidence and clinical usefulnessAdverse Effects of GLP-1 Receptor AgonistsThe Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in KoreaBasal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision makingThe evolution of insulin glargine and its continuing contribution to diabetes careCombining incretin-based therapies with insulin: realizing the potential in type 2 diabetesLixisenatide as add-on therapy to basal insulinTreatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitorsEffects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetesUpdate on the treatment of type 2 diabetes mellitusTreatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonistsComparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic reviewEfficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review.Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes.Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-AnalysisLixisenatide: first global approval.Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes--a study in both people with type 2 diabetes and healthy subjects.The clinical development program of lixisenatide: a once-daily glucagon-like Peptide-1 receptor agonist.Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin.Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-SInjectable Coformulations in DiabetologyNovel Agents for the Treatment of Type 2 Diabetes.Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-AnalysisComparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor AgonistsTherapeutic Options for the Management of Postprandial Glucose in Patients With Type 2 Diabetes on Basal Insulin.Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trialsHow much is too much? Outcomes in patients using high-dose insulin glargine.Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies.Combination therapy of glucagon-like peptide-1 receptor agonists and insulin for patients who developed diabetes after partial pancreatectomyCombination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature.Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis.Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitusPreoperative use of incretins is associated with increased diabetes remission after RYGB surgery among patients taking insulin: a retrospective cohort analysis.Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).
P2860
Q24568148-40F20271-8732-4E63-8358-C68F5C2FF1A0Q26767260-CE636C21-FC88-48BB-8E3F-180EBD45D106Q26771823-29FA4E22-6AD9-4E17-95DA-A9F4BD2D34B0Q26801346-07B506B1-B1AA-4333-8557-806D519397FEQ26852590-8C80B9FA-41B2-495A-AFE2-9C6A7383B687Q26992979-58B1B6BC-AAE3-4C74-BA5F-5C16B3B16F08Q26999454-D6784C94-0C3C-425B-9ED9-BDF95B87D10CQ27004723-F2FE17AF-04FB-430E-855C-755DED8E449BQ27007547-2C965BE0-CF92-4F11-A5ED-6B596ECF146FQ27021870-18958566-86AB-4692-BFA2-11B763DAC758Q27025423-4B752627-954D-49D0-8789-EE23B820A5B1Q28073342-811CFEFB-C299-490B-850F-B964BCAEA3B2Q28077026-B49748B2-EF25-4A29-A502-798953B02A35Q28540671-F7B778E3-37F4-4BE8-9984-F0095A2E934BQ30240808-DE52EAC2-7727-4AF3-90A3-5A6079CA4DC6Q30249371-086F0988-531B-4719-9AD6-B839975F8171Q30253045-E8AF1246-F226-408B-9518-962D0FDBC7C5Q31140045-DCCAA9CC-B791-4B04-8848-22A27076D1C9Q34337281-1F816E16-FF91-4982-AD2D-645DD60D4969Q34543003-3446FD5D-FBFA-4641-BE49-05B9A0E8053DQ34726309-375FDD7E-7789-47FA-8066-BF3A6791B85DQ35035176-969C9C53-4337-48ED-A36C-81D4F611448AQ35192193-64773B98-9BB0-4F2A-87C2-61E9D24FFC59Q35772586-5E3CE40E-D616-4A15-822C-4EE5746D1954Q35910421-222AE4CD-898D-403C-BD76-9260EDFBD2BEQ36011993-64BE35C8-6D88-435E-8574-75FC7C8BFEE9Q36073461-96691639-4472-4DD9-9C75-B5EF4507357EQ36169413-D2D03A00-C8A5-4D3C-A1B3-B20DD2635CE2Q36303980-EF0156C4-3342-44A5-A4D4-57B4BC9EC352Q36536807-3F7683E5-33C1-4908-86BB-21F85A6F0166Q36554216-6F88205C-18B5-45EF-826A-1C845EA17370Q36712701-AEC7B97F-A9D2-4A09-94B4-B087D599F93FQ36803151-D8C3D002-5660-482C-9B2B-B2F36336B1BDQ36843912-9EAE8329-70A8-4825-9C50-DD7BACE61709Q36872178-1605DAC0-B6BA-46FA-A117-66CBA2FEAE92Q36955106-36F8F314-F401-42AC-9EE8-88D0D6B256CCQ36972371-FD36D4EC-638D-445D-90FC-B45D3A54478AQ36978258-C6D61B03-3AB2-49D8-AA0D-AA2EC446AAC6Q37106537-8DD5CBAB-BD86-4364-9164-6484826DC483Q37106572-7FDC3999-0BCB-43F9-AEAC-AA14C8100761
P2860
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Randomized, double-blind, plac ...... sulfonylurea (GetGoal-L-Asia).
@ast
Randomized, double-blind, plac ...... sulfonylurea (GetGoal-L-Asia).
@en
type
label
Randomized, double-blind, plac ...... sulfonylurea (GetGoal-L-Asia).
@ast
Randomized, double-blind, plac ...... sulfonylurea (GetGoal-L-Asia).
@en
prefLabel
Randomized, double-blind, plac ...... sulfonylurea (GetGoal-L-Asia).
@ast
Randomized, double-blind, plac ...... sulfonylurea (GetGoal-L-Asia).
@en
P2093
P2860
P921
P1476
Randomized, double-blind, plac ...... sulfonylurea (GetGoal-L-Asia).
@en
P2093
E Niemoeller
EFC10887 GETGOAL-L Asia Study Investigators
P2860
P304
P356
10.1111/J.1463-1326.2012.01618.X
P577
2012-05-30T00:00:00Z